Ziva DRA helps pharmaceutical, medical device, diagnostic, cosmetics and healthcare companies understand the competitive environment around their products—covering market participants, product portfolios, positioning, commercial channels and relevant regulatory context.
Competitive analysis should show how companies, brands, products, channels and regulatory positions interact within the target market.
A competitor list alone rarely answers the strategic questions behind market entry. Companies need to understand what competitors offer, how their portfolios are structured, where they appear in the market and how those positions may affect a new entrant.
Ziva DRA structures competitor analysis around the specific product category and decision being evaluated, rather than treating all market participants as equally relevant.
For regulated healthcare products, competitor intelligence can also be interpreted alongside regulatory and market-access considerations so the commercial picture remains realistic.
The exact research scope can be adapted around the product category, market-entry stage and strategic question.
Identify relevant manufacturers, brands, suppliers or other market participants within the defined competitive landscape.
Compare product categories, offerings, technologies and portfolio breadth across relevant competitors.
Assess visible positioning, target segments and potential differentiation patterns within the market.
Examine distribution, commercial presence and relevant routes through which competitors participate in the market.
Include relevant registration or regulatory information where it contributes to understanding competitive market access.
Translate the competitive picture into potential entry, positioning and intelligence priorities.
The analysis should narrow the market into the competitors most relevant to the decision being made.
The final framework depends on available information, product type and the client's strategic objective.
Build a structured view of the principal companies and offerings within the target landscape.
Competitive findings can be connected with broader market-entry and regulatory considerations.
Competitor, device-portfolio and market-positioning analysis.
Diagnostic brand, technology and market-participant intelligence.
Product, portfolio and competitive market analysis for pharmaceuticals.
Brand, product and commercial-positioning analysis for consumer-facing categories.
Competitive intelligence becomes valuable when it changes how a company approaches market entry, positioning or further research.
Understand which companies and products shape the target landscape.
Identify areas where the market may appear crowded, underserved or differentiated.
Develop a clearer view of how a product may need to differentiate.
Use competitive context to strengthen market-entry and research planning.
Depending on the scope, it can include competitor identification, product portfolios, positioning, market presence, channels and relevant regulatory context.
Yes. The project can be narrowed to a specific device, diagnostic, medicine, cosmetics category or other agreed market segment.
Yes, where relevant and available. Regulatory context can help explain market presence and potential market-access differences among competitors.
Yes. Portfolio mapping can be included to understand product breadth, category focus and visible competitive overlap.
Yes. The analysis can begin with remote discussions about the product, target segment and competitive questions the company needs answered.
The competitor analysis can identify questions that warrant additional Market Research, Market Overview or regulatory intelligence work.
Share your product, target segment and known competitors with Ziva DRA. We can structure a competitor-analysis project around the commercial and regulatory questions most relevant to your market-entry decision.